The second session of the Symposium brought us to key clinical end points, the ischemic heart and cancer, in which the many faces of AMP-activated protein kinase (AMPK) were highlighted. Session 3 was devoted to the role of AMP kinase and its metabolic relatives, malonyl CoA and carnitine palmitoyl transferase 1 (CPT-1), in the control of energy balance by the central nervous system. Following are some highlights of these exciting presentations.
AMP kinase in the heart
As discussed earlier in the Symposium, AMPK acts as a fuel gauge in the cell. Such a role is particularly important in the heart, a muscle with a high energy demand and in which there is very little stored energy. AMPK is activated under metabolic stress, one such stress being cardiac ischemia. This condition is highly prevalent, being the major cause of death in western societies. When ischemia occurs, AMPK is rapidly activated and stimulates glucose uptake, glycolysis and fatty acid oxidation. As highlighted by Gary Lopaschuk, these metabolic effects of AMPK activation can have both beneficial and deleterious consequences in the heart muscle when oxygen supply is compromised.
In the heart, adenosine triphosphate needed to sustain contractile function and basal metabolism is supplied primarily by mitochondrial oxidative metabolism and, to a much lesser extent, by glycolysis. The heart is able to use several energy sources, however, 60-90% comes from fatty acid oxidation and 10-40% from pyruvate (derived from glycolysis or lactate) oxidation. As in other oxidative tissues, in the heart the entry of fatty acids into the mitochondrion for oxidation is controlled by the activity of CPT-1, itself under the inhibitory control of malonyl CoA. Intracellular malonyl CoA levels represent the balance between synthesis from acetyl CoA (acetyl CoA carboxylase, ACC) and degradation back to acetyl CoA (malonyl CoA decarboxylase). Both ACC and malonyl CoA decarboxylase are thought to be controlled through phosphorylation by AMPK. Through such modulation of key enzymes, AMPK plays an important role in the control of cardiac fatty acid oxidation. The other important substrate for ATP production in the heart is glucose. Pyruvate dehydrogenase, which converts pyruvate to acetyl CoA, constitutes an important modulatory node in cardiac glucose oxidation. High plasma non-esterified fatty acid levels favor their uptake by the heart, and their oxidation inhibits that of glucose (the Randle cycle) and pyruvate dehydrogenase activity. Conversely, low fatty acid oxidation favors glucose uptake and pyruvate dehydrogenase activity, pyruvate oxidation and cardiac efficiency (work per unit O 2 consumed).
The formation of ATP from glucose is divided into two distinct pathways, glycolysis and glucose oxidation. Glycolysis, which can proceed in the absence of O 2 , breaks down glucose to pyruvate, which yields some ATP (less than 10% of total ATP in the normal heart). Mitochondrial oxidation of pyruvate yields the remaining 90% of glucose-derived ATP. Glucose/glycogen metabolism in the heart is catalyzed by many enzymes, several being under phosphorylation/dephosphorylation control, in which AMPK plays a central role.
In the mildly ischemic myocardium (for example, angina), mitochondrial ATP generation cannot keep up with demand, so glycolysis increases to compensate. It actually becomes the major source of ATP under severe ischemia (for example, infarct, surgery). Glycolysis is, however, uncoupled from glucose oxidation, and deleterious by-products of glycolysis (lactate and protons) begin to accumulate. ATP is then used to clear such by-products, hence reducing cardiac function and efficiency. Upon reperfusion following ischemia, the extent of recovery is dependent upon the type of substrate metabolized. Fatty acid oxidation can increase dramatically and reduce glucose oxidation (Randle cycle), due to high circulating non-esterified fatty acid levels often seen during ischemia and also due to direct alterations in the control of fatty acid oxidation. Uncoupling of glycolysis from glucose oxidation is therefore maintained, as is the reduction in cardiac efficiency during the critical reperfusion period. Gary Lopaschuk's group has shown that AMPK is dramatically activated during ischemia, presumably in an attempt to turn on ATP generating pathways. AMPK activation does increase both glucose and fatty acid metabolism in the ischemic heart. Such rapid AMPK activation is thought to involve both a change in intracellular AMP concentration and activation of upstream AMPK kinases. Which of these kinases is important in AMPK phosphorylation during ischemia remains unknown. Of note is the fact that cardiac AMPK phosphorylation is also under hormonal control. Adiponectin may activate AMPK through such phosphorylation, whereas insulin has the opposite effect. An inverse relationship exists in which AMPK activation can inhibit cardiac insulin signaling, thereby completing a negative feedback loop.
AMPK activation in the ischemic heart increases the heart potential for glucose utilization and anaerobic ATP synthesis. At the same time, AMPK activation during ischemia stimulates fatty acid oxidation through inhibition of ACC-catalyzed malonyl CoA formation. Unfortunately, given the lower overall capacity for oxidative metabolism under ischemia, increased lipid oxidation occurs at the expense of glucose oxidation, which may be detrimental under ischemia/reperfusion conditions. Whether AMPK activation is beneficial or harmful to the ischemic heart remains an open question. The increase in the overall oxidative capacity brought about by AMPK activation would be considered beneficial, however, increased fatty acid oxidation would tend to impair that of glucose with a consequent increase in proton production (through glycolysis), thereby decreasing cardiac function and efficiency during the critical reperfusion period. In addition, the consequences of AMPK activation on heart function following ischemia may depend upon the energy substrates available to the heart. For instance, ischemic events in humans frequently occur in the presence of high concentrations of fatty acids in the circulation. Experimental models will have to factor in this potentially important determinant of the metabolic outcome of AMPK activation. Intuitively, AMPK activation and the concomitant increase in mitochondrial fatty acid oxidation appears desirable in tissues such as skeletal muscle and the liver to reduce lipotoxicity. The jury is, however, still out as to whether AMPK activation is beneficial or deleterious to the ischemic heart.
AMP kinase in cancer
Whereas under normal conditions AMPK constitutes a sensitive fuel gauge in oxidative tissues such as skeletal and cardiac muscle and the liver, it possesses the capacity to play a central regulatory role in cell growth, with particular relevance to cancer cell development, as discussed by Francis P Kuhajda. Once thought to be a consequence of cellular transformation that defines the malignant phenotype, cellular energy metabolism has gained renewed attention with the identification of LKB1, one of several upstream AMPK kinases, as a tumor suppressor gene that is mutated in the rare Peutz-Jegher familial cancer syndrome. Complete loss (two inactivating lesions) of LKB1 function in Peutz-Jegher patients promotes the development of cancer in a variety of organs. Conversely, pharmacological AMPK activation has recently been reported to be cytotoxic to many human cancer cell lines and cancer xenografts. These observations point to AMPK as a potentially important regulator of cancer cell survival. Given that the cancer cell shows a marked predilection for aerobic glycolysis over mitochondrial respiration to generate ATP, strategies to alter cellular energy metabolism through AMPK may provide novel cancer therapies.
The defect in LKB1 that characterizes the Peutz-Jegher cancer syndrome supports the notion that the inability to activate AMPK favors the development of cancer. AMPK inactivation could drive cell proliferation and growth through mammalian target-of-rapamycin signaling. In cells with intact LKB-1/AMPK signaling, energy depletion would lead to retardation or arrest of cell growth until restoration of ATP levels. With the loss of LKB-1, which eliminates the AMPK-dependent metabolic checkpoint for cell growth and proliferation, such growth retardation would not occur in times of reduced energy availability, leading to the malignant phenotype. In normal tissues, functional LKB-1/AMPK signaling may therefore protect against malignancy.
AMPK activation appears to be cytotoxic in transformed (malignant) cells, inducing apoptosis or growth arrest, possibly via acting on the Akt oncogene. Akt appears to play an important role in maintaining a peculiar metabolic profile in the cancer cell consisting of concomitant increases in aerobic glycolysis, lipogenesis, nucleic acid and protein synthesis with reduced fatty acid oxidation, a profile that promotes and maintains the malignant phenotype. As a tumor grows, energy availability may become limiting, and AMPK becomes activated in an attempt to restore cellular energy balance. To do so, activated AMPK interferes with anabolic activity through inhibition of Akt signaling, either directly or via the mammalian target-of-rapamycin. The resulting reduction in macromolecule formation and increase in fatty acid oxidation for ATP generation combines with AMPK-mediated activation of p53, leading to cell cycle arrest.
Physiological AMPK activation appears to be antiapoptotic, maintaining the integrity of the cancer cell in times of energy deprivation until energy becomes available again. In contrast, given the right conditions, the rapid pharmacological activation of AMPK appears to promote cancer cell death through negative alterations in fatty acid, nucleic acid or protein synthesis that the malignant cell cannot tolerate. This opens up new possibilities for the manipulation of AMPK activity as treatment for cancer.
AMP kinase in heart, cancer and CNS Y Deshaies
When considering AMPK activation as an anticancer therapy, it must be remembered that the pleiotropic actions of pharmacological AMPK activation in normal cells could be problematic. Ideally, selective activation in cancer cells would avoid such potential complications. Dr Kuhajda's recent work on fatty acid synthase (FAS) inhibition in human cancer cells provides one promising approach to achieve such selectivity. Using the AMPK inhibitor Compound C, his group was able to show that the cytotoxicity of FAS inhibition in cancer cells was largely due to AMPK activation. Cancer cells commonly express high levels of FAS, but only a few normal human tissues do so, providing one promising avenue for achieving cytotoxic activation of AMPK that is cell-specific.
Older knowledge regarding energy metabolism of cancer cells, the identification of rare mutations in a gene coding for a protein that acts both as a tumor suppressor and as a modulator of AMPK, and recent discoveries related to the control of this metabolic sensor at the molecular level have been brought together to provide an original and promising new approach to treat cancer.
AMP kinase in the central nervous system
Glucose-sensing neurons were identified decades ago, and we all learned that neurons consume glucose as their main source of energy. Recent work, however, has put into light new players in the arena of central nutrient sensing, identifying fatty acid metabolism and some of its components, including AMPK, as key determinants of the regulation of energy balance by the brain. In addition, Gabriele V Ronnett's research on the function of AMPK in the brain reveals relevant relationships with work presented in the preceding session, namely inhibition of FAS as a means of modulating AMPK activity, and ischemic stress.
In the context of preventing and treating obesity, targeting any one of the many central nervous system neuroendocrine modulators of energy balance is often found to be compensated by other systems left intact. Targeting, instead, molecules most fundamental for energy metabolism may represent a valuable option. Recent study has shown that hypothalamic AMPK is a major player in the regulation of whole-body energy balance. For Gabriele Ronnett's group, the story began with C75, the FAS inhibitor that also stimulates CPT-1 and fatty acid oxidation. FAS catalyzes the de novo synthesis of fatty acids. It acts in concert with ACC, which generates malonyl CoA from acetyl CoA, both required for fatty acid synthesis. Both FAS and ACC are regulated transcriptionally, ACC being rate-limiting for fatty acid synthesis; the enzymes are activated when cellular energy is in surplus and downregulated in times of energy depletion. Energy surplus is associated with high production rates of the FAS substrate, malonyl CoA, which also inhibits CPT-1 to prevent oxidation of the newly synthesised fatty acids. C75 prevents elongation of the acyl chain and thus blocks fatty acid synthesis, and also competes with malonyl CoA, relieving CPT-1 inhibition and potently increasing fatty acid oxidation and ATP levels.
Central administration of C75 decreases food intake and body weight, and evidence suggests that it acts through modulation of the balance between orexigenic and anorexigenic neuropeptides. Ronnett's group showed that C75 prevented the hypophagia-induced activation of the medial arcuate nucleus, an important hypothalamic integrator of the response to food deprivation, as well as that of some of its target regions (lateral hypothalamus, paraventricular nucleus, dorsomedial hypothalamus) associated with orexigenic neuropeptide production. Conversely, C75 infusion increased neuronal activation in the parvocellular paraventricular nucleus that contains anorexigenic neuropeptides. It was then shown in primary cortical and hypothalamic neuronal culture systems that C75 decreased FAS activity, increased that of CPT-1, promoted oxidation of both glucose and fatty acids, and increased cellular ATP levels in a biphasic manner. Importantly, phosphorylated (activated) AMPK (pAMPK) was modulated exactly in the opposite direction, as would be predicted by changes in the AMP/ATP ratio, a major modulator of AMPK activity.
Once it was shown that C75 affected AMPK activation, various pharmacological tools were used to establish that AMPK is a physiological mediator of the effects of C75 on energy balance. The AMPK inhibitor Compound C decreased feeding and body weight, mimicking C75, whereas the AMPK activator, 5-aminoimidazole-4-carboxamide ribonucleoside, increased food intake. This pharmacological work is congruent with that of others using constitutively active or dominant negative AMPK-containing adenoviral vectors. Collectively, the data indicate that altering hypothalamic AMPK activity is sufficient to elicit changes in feeding behavior. Also, evidence suggests that the state of activation of AMPK is modified in response to changes in the body energy status. Mechanisms linking altered AMPK to feeding behavior are beginning to emerge. AMPK and the orexigenic neuropeptide Y colocalize in the medial arcuate nucleus. A C75-mediated decrease in pAMPK is associated with suppression of neuropeptide Y expression; conversely, 5-aminoimidazole-4-carboxamide ribonucleoside increases both pAMPK and neuropeptide Y expression. A link is therefore established between AMPK activity and expression of neuropeptides involved in the control of food intake. The above evidence supports the notion that increased cellular ATP and decreased AMPK activity in energy-sensing hypothalamic neurons are interpreted as 'energy surfeit' signals, soliciting neuroendocrine pathways that ultimately decrease energy intake (and likely also increase energy expenditure). The exact nature of the intracellular signal that triggers neuropeptide expression/ release in response to altered AMPK activation remains elusive, however, AMPK signaling to ingestive behavior is beginning to be unraveled, as discussed in the next presentation.
AMP kinase in heart, cancer and CNS Y Deshaies
Under normal physiological conditions, AMPK plays the role of sensing the energy status of hypothalamic neurons involved in whole-body energy balance. It should be remembered, however, that enzymes such as FAS, CPT-1 and AMPK are ubiquitously expressed in the brain. Energy sensing could then conceivably impact neuronal activity in extra-hypothalamic regions, not involved in energy balance regulation, under pathological conditions associated with profound disturbances in cellular energy metabolism, ischemia being one germane example. Ischemic cells are subjected to excitotoxic and oxidative damage and attempt to repair such damage by activation of energy-consuming processes that, if uncontrolled, can lead to complete energy loss and cell death. Ronnett's group found that such state of ATP depletion, as expected, activates AMPK, not only in ischemic brain areas, but also in intact contralateral areas, indicating the existence of a global signal for AMPK activation. Remarkably, pharmacological inhibition of such activation was shown to dramatically reduce ischemia-related brain damage. Therefore, as discussed earlier on in the case of the ischemic heart and the cancer cell, future development of various AMPK-based therapies will have to carefully weigh in the energy status at the tissue-specific level.
Malonyl CoA in the central nervous system
As noted above, the nature of the intracellular signals that trigger neuropeptide expression in hypothalamic neurons in response to altered AMPK activation is not yet established. The work of M Daniel Lane provides enticing evidence in support of two candidates that are metabolically linked to AMPK, namely malonyl CoA and a novel, brain-specific isoform of CPT-1.
The dramatic reduction in food intake elicited by the administration of the FAS inhibitor C75 discussed above is strongly correlated with increased hypothalamic malonyl CoA concentration. Such build-up is expected because malonyl CoA is the substrate for FAS. As a reminder, there is an important metabolic link between AMPK and malonyl CoA: AMPK phosphorylates (deactivates) ACC, the enzyme that generates malonyl CoA from acetyl CoA. Therefore, AMPK activation in the hypothalamus reduces malonyl CoA (and increases food intake), whereas AMPK inhibition (for example, with Compound C) exerts the opposite effect. To demonstrate that FAS inhibition reduces food intake via increasing malonyl CoA, an ACC inhibitor was given centrally prior to C75. Prevention of the build-up of malonyl CoA thus achieved totally abolished the reduction in food intake, thereby validating the malonyl CoA hypothesis.
As a digression relevant to energy balance regulation, the work of Lane's group has established that weight loss induced by FAS inhibitors is not entirely due to reduced food intake, but also to increased energy expenditure. Even when administered centrally, FAS inhibitors bring about a rapid increase in muscle fatty acid oxidation that is associated with inactivation of ACC, reduced malonyl CoA, consequent derepression of CPT-1 (the CPT-1b isoform in muscle) and a rapid (within 3 days) increase in mitochondrial mass in skeletal muscle. These effects are believed to involve the sympathetic nervous system as the mediator of the central malonyl CoA signaling to muscle.
Additional validation of the malonyl CoA hypothesis was obtained by manipulating the expression of genes that modulate malonyl CoA levels. Malonyl CoA decarboxylase, which catalyzes the conversion of malonyl CoA to acetyl CoA (the opposite of the ACC-catalyzed reaction) was first examined. As predicted by the hypothesis, introduction of an adenoviral-malonyl CoA decarboxylase expression vector in the ventral hypothalamus (expected to lower malonyl CoA) increased food intake and weight gain and reversed the anorectic action of C75. Others used a FAS knockdown approach that resulted in a phenotype (reduced food intake and body fat) consistent with pharmacological FAS inhibition, and Lane's group went on to show that hypothalamic FAS disruption increases hypothalamic malonyl CoA levels.
Recent evidence suggests that physiological modulation of hypothalamic malonyl CoA, including changes between the fasted and fed states, occurs through alterations in ACC activity by AMPK. It is currently speculated that during fasting the AMP/ATP ratio increases in the critical hypothalamic nuclei, leading to the activation of AMPK, inactivation of ACC and a consequent decrease in malonyl CoA, which ultimately triggers ingestive behavior.
The various lines of evidence discussed above make a strong case for the importance of hypothalamic malonyl CoA in the regulation of energy balance. One major question that remains is what happens downstream of malonyl CoA. Our speaker's recent work on this issue has led to the discovery of CPT-1c and to the evidence that it may constitute the next step in malonyl CoA signaling to energy balance neuropeptides. Unlike the a and b isoforms, CPT1c is specific to the brain, where CPT1a has limited expression, and is expressed in brain regions involved in energy balance regulation. Surprisingly, despite its analogy to the other isoforms and its shared malonyl CoA-binding properties, CPT1c does not catalyze acyl transfer to carnitine nor enhance fatty acid oxidation in the in vitro setting, and its end products are unknown. The physiological role of CPT1c was further addressed through gene invalidation. CPT1c knockout mice fed a low-fat (chow) diet were found to be leaner than their wildtype counterparts due to lower food intake, however, they proved to gain more weight when fed a high-fat diet, suggesting a protective role for CPT1c against high-fat dietinduced obesity. Although the molecular mode of action of CPT1c remains unclear, long-chain fatty acyl CoAs are vastly increased in the hypothalamus of KO mice, indicating that CPT1c is necessary for fatty acid metabolism in this brain region. How such alterations in local fatty acid metabolism AMP kinase in heart, cancer and CNS Y Deshaies are related to AMPK and malonyl CoA metabolism and to neuroendocrine regulation of whole-body energetics remains to be resolved.
Lessons learned from sessions 2 and 3
A first message to be taken home from the presentations is the remarkable integration of the function of a ubiquitously expressed metabolic sensor between the brain and the periphery. In times of energy deprivation, AMPK is not only activated in peripheral tissues to favor local ATP production, but also in the brain to stimulate neuroendocrine pathways that increase food intake. AMPK activation thus puts the whole organism into gear for energy acquisition. A second message might be one of caution: strategies aimed at increasing AMPK activity at the level of the whole organism may be effective in ameliorating insulin action and reducing lipotoxicity in tissues such as the liver and skeletal muscle; however, stimulation of food intake would have to be considered, as well as potential untoward effects in the ischemic heart, the 'ischemic' (under-vascularized) cancer cell and the ischemic brain. In this context, tissue specificity (perhaps based on the multiple combinations of AMPK subunits) and optimal dosage would probably constitute valuable aspects to be considered. A third message is one of excitement. The research presented in these sessions of the Symposium points to vast possibilities for controlling how the brain perceives the energy status of the body, and for optimizing energy substrate metabolism and cell growth in a variety of peripheral organs through modulation of energy sensors.
